Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include MarketWatch, Bloomberg.com and qz.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 8h ago.
Quick answers
Why is "Lilly reports second-quarter 2026 financial results, raises full-year guidance, " trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares barrons.com · 10h ago
- Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand WSJ · 10h ago
- Lilly’s revenue soars 48%, driven by demand of its GLP-1s MarketWatch · 10h ago
- Lilly Boosts Sales Guidance on Strong Demand for Obesity Drugs Bloomberg.com · 10h ago
- Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast qz.com · 10h ago
Topics
Related trends
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.